Register for our free email digests:
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
The smart money had increasingly been on a hung parliament in the UK, with the ruling Conservative party being punished for several policy slip-ups, perceived dithering by Prime Minister Theresa May and her insistence on a clean and hard Brexit led by her alone. The June 8 election did not need to be called, and today, May is ruing the fact that she has lost both the party's absolute majority and her mandate to lead on a hard Brexit.
Latest From Market Access
Pharmas were in the minority at WHO's Fair Pricing Forum, but ZS' Ed Schoonveld says that other attendees sent some messages that pharma CEOs should heed.
Health technology assessment for medtech products in Europe is a strictly national responsibility, but is there a case for an EU-wide HTA system that could improve medtech market access? MedTech Europe chief executive Serge Bernasconi shares his views with In Vivo.
ASCO’s 2017 annual meeting is expanding its focus on patient wellness beyond the clinic, with new research highlighting prevention, alternative treatments post-surgery, psycho-social factors and other issues reflecting the concerns of a growing new constituency of cancer survivors. In Vivo discusses this year’s agenda with ASCO’s CMO, Richard Schilsky.
Preventing cyberattacks on medical technology occupies the waking thoughts of device software manufacturers, but the global ransomware episode in mid-May shows that companies must also be alive to threat posed to their provider customers.
Labeling, logistics and other issues were on the table as industry experts discussed the potential upcoming launches of CAR-T therapies in the US. Datamonitor Healthcare reported live from the ARM conference.
Transparency is an issue that continues to pose reputational challenges for biopharma. A key flashpoint is the disclosure – under open access rules – of clinical trial data in a climate of mounting therapeutic competition. Still, some industry players are pushing the boundaries around open access. Project Data Sphere, a non-profit group backed by the CEO Roundtable on Cancer, is taking advantage of new IT platforms and the rich target potential in discovery science to press for a larger industry consensus around new ways to release high-value data embedded in years of trials, all for the benefit of cancer patients.
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.